AnalystsVikram PurohitVikram Purohit's Stock Forecasts
AnalystsVikram Purohit
Analyst Ranking
Bottom 5%
#4796 out of 5017 analysts
Average Return
-13.51%
Win Rate
22%14 out of 64
Risk vs Reward
Poor
Good
Vikram Purohit's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Arcutis Biotherapeutics IncARQT | +385.78% | $2.11 | $10.25 | 2023-11-12 - 2024-11-12 | Strong Buy |
Pandion Therapeutics IncPAND | +219.36% | $18.85 | $60.20 | 2020-08-10 - 2021-02-26 | Strong Buy |
Zenas Biopharma IncZBIO | +139.63% | $9.16 | $21.95 | 2024-12-10 - 2025-09-15 | Strong Buy |
Axsome Therapeutics IncAXSM | +45.53% | $73.69 | $107.24 | 2024-04-28 - 2025-04-28 | Strong Buy |
Incyte CorpINCY | +29.36% | $74.18 | $95.96 | 2020-03-31 - 2020-04-29 | Strong Buy |
Vikram Purohit Analyst Color
Get additional color on Vikram Purohit's coverage of popular stocks
Vikram Purohit's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Absci CorpABSI | 3 | Strong Buy | $5.89 | +124.81% | Maintains | a month ago |
Halozyme Therapeutics IncHALO | 10 | Strong Buy | $80.00 | +4.81% | Maintains | a month ago |
Recursion Pharmaceuticals IncRXRX | 4 | Hold | $5.00 | +4.82% | Assumes | 2 months ago |
Ascendis Pharma AASND | 19 | Strong Buy | $250.00 | +28.46% | Upgrades | 4 months ago |
Incyte CorpINCY | 15 | Hold | $65.00 | -21.82% | Maintains | 6 months ago |
Axsome Therapeutics IncAXSM | 17 | Strong Buy | $190.00 | +62.71% | Maintains | 7 months ago |
Zenas Biopharma IncZBIO | 2 | Strong Buy | $35.00 | +59.45% | Maintains | 9 months ago |
Foghorn Therapeutics IncFHTX | 8 | Hold | $9.00 | +80.36% | Maintains | a year ago |
Genmab AGMAB | 2 | Hold | $31.00 | N/A | Maintains | a year ago |
Acelyrin IncSLRN | 7 | Hold | $6.00 | N/A | Maintains | a year ago |
Exscientia PLCEXAI | 16 | Hold | $7.00 | N/A | Maintains | a year ago |
Abivax SaABVX | 2 | Hold | $16.00 | N/A | Maintains | a year ago |
Compass Pathways PLCCMPS | 1 | Strong Buy | $30.00 | N/A | Initiates Coverage On | a year ago |
Sage Therapeutics IncSAGE | 6 | Hold | $22.00 | N/A | Maintains | 2 years ago |
Arcutis Biotherapeutics IncARQT | 8 | Strong Buy | $10.00 | N/A | Maintains | 2 years ago |
Ventyx Biosciences IncVTYX | 1 | Hold | $6.00 | N/A | Downgrades | 2 years ago |
Regenxbio IncRGNX | 7 | Strong Buy | $42.00 | N/A | Maintains | 2 years ago |
Evelo Biosciences IncEVLO | 4 | Hold | $10.00 | N/A | Maintains | 2 years ago |
Hookipa Pharma IncHOOK | 4 | Hold | $22.50 | N/A | Maintains | 2 years ago |
Tourmaline Bio IncTRML | 5 | Hold | $3.00 | N/A | Maintains | 3 years ago |
Akili IncAKLI | 2 | Hold | $3.00 | N/A | Maintains | 3 years ago |
Kymera Therapeutics IncKYMR | 8 | Hold | $41.00 | N/A | Maintains | 3 years ago |
Instil Bio IncTIL | 7 | Hold | $40.00 | N/A | Maintains | 3 years ago |
Prokidney CorpPROK | 1 | Hold | $13.00 | N/A | Initiates Coverage On | 3 years ago |
Schrodinger IncSDGR | 4 | Hold | $38.00 | N/A | Maintains | 3 years ago |
Certara IncCERT | 4 | Hold | $20.00 | N/A | Maintains | 3 years ago |
Theravance Biopharma IncTBPH | 6 | Strong Sell | $10.00 | N/A | Maintains | 3 years ago |
Radius Health IncRDUS1 | 3 | Strong Sell | $7.00 | N/A | Downgrades | 4 years ago |
Tscan Therapeutics IncTCRX | 1 | Strong Buy | $22.00 | N/A | Initiates Coverage On | 4 years ago |
Pandion Therapeutics IncPAND | 2 | Hold | $60.00 | N/A | Downgrades | 5 years ago |
Dbv Technologies SaDBVT | 2 | Hold | $20.00 | N/A | Maintains | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.